Cynata Therapeutics Ltd
ASX:CYP
Cynata Therapeutics Ltd
ASX:CYP
Price:
0.28
AUD
-1.75%
Market Closed
Market Cap:
AU$66.5m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Cynata Therapeutics Ltd
ASX:CYP
|
AU |
|
Hillman Solutions Corp
NASDAQ:HLMN
|
US |
|
T
|
Tasco JSC
VN:HUT
|
VN |
|
Macromill Inc
TSE:3978
|
JP |
|
Samsung Fire & Marine Insurance Co Ltd
KRX:000810
|
KR |
|
Mako Gold Ltd
ASX:MKG
|
AU |
|
B
|
Banco Bradesco SA
SWB:BREC
|
BR |
|
G
|
Guangdong LingXiao Pump Industry Co Ltd
SZSE:002884
|
CN |
|
C
|
Chukyo Bank Ltd
TSE:8530
|
JP |
|
Melco Holdings Inc
TSE:6676
|
JP |
|
T
|
TriSalus Life Sciences Inc
NASDAQ:TLSI
|
US |
|
I
|
Isata Ltd
TASE:ISTA
|
IL |
|
Fuji Oil Holdings Inc
TSE:2607
|
JP |
|
S
|
Solaer Renewable Energies Ltd
TASE:SOLR
|
IL |
|
SK Innovation Co Ltd
KRX:096770
|
KR |
|
AAK AB (publ)
OTC:ARHUF
|
SE |
Relative Value
The Relative Value of one
CYP
stock under the Base Case scenario is
hidden
AUD.
Compared to the current market price of 0.28 AUD,
Cynata Therapeutics Ltd
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CYP Relative Value
HIDDEN
Multiples Across Competitors
CYP Competitors Multiples
Cynata Therapeutics Ltd Competitors
Cynata Therapeutics Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| AU |
|
Cynata Therapeutics Ltd
ASX:CYP
|
66.5m AUD | 326.9 | -7.9 | -7.6 | -7.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
366.3B USD | 6 | 87.5 | 14.5 | 20.2 | |
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
355.9B USD | 109.6 | -1 710.6 | 15 890.6 | -1 794.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
190.8B USD | 5.2 | 24.7 | 14.3 | 14.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
171.4B USD | 5.8 | 20.2 | 12.6 | 15.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.9B USD | 9.6 | 29.2 | 22 | 23 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.4B USD | 5.5 | 17.6 | 13 | 14.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67.2B AUD | 3.1 | 34.4 | 11.4 | 14.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
